These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21606474)

  • 21. Safety and efficacy of locally applied imiquimod cream 5% for the treatment of condylomata acuminata of the vulva.
    Haidopoulos D; Diakomanolis E; Rodolakis A; Vlachos G; Elsheikh A; Michalas S
    Arch Gynecol Obstet; 2004 Dec; 270(4):240-3. PubMed ID: 14648072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of imiquimod in anogenital warts from HIV-positive men.
    Herrera S; Correa LA; Wolff JC; Gaviria A; Tyring SK; Sanclemente G
    J Clin Virol; 2007 Jul; 39(3):210-4. PubMed ID: 17513167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial.
    Kumar P; Dar L; Saldiwal S; Varma S; Datt Upadhyay A; Talwar D; Sharma VK; Verma KK; Dwivedi SN; Raj R; Gupta S
    JAMA Dermatol; 2014 Oct; 150(10):1072-8. PubMed ID: 25103148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases.
    Davis G; Wentworth J; Richard J
    J Reprod Med; 2000 Aug; 45(8):619-23. PubMed ID: 10986679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mood changes in patients on topical imiquimod].
    Brenaut E; Coquart N; Garlantezec R; Herault M; Schoenlaub P
    Ann Dermatol Venereol; 2012 Feb; 139(2):145-8. PubMed ID: 22325757
    [No Abstract]   [Full Text] [Related]  

  • 26. Imiquimod (Aldara cream).
    Buck HW
    Infect Dis Obstet Gynecol; 1998; 6(2):49-51. PubMed ID: 9702584
    [No Abstract]   [Full Text] [Related]  

  • 27. Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases.
    Rosenblatt A; de Campos Guidi HG
    Int J STD AIDS; 2012 Dec; 23(12):909-10. PubMed ID: 23258837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata.
    Dede M; Kubar A; Yenen MC; Alanbay I; Guven S; Mesten Z; Baser I
    Acta Obstet Gynecol Scand; 2007; 86(8):968-72. PubMed ID: 17653883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasiform eruption and oral ulcerations as adverse effects of topical 5% imiquimod treatment in children: a report of four cases.
    Smith WA; Siegel D; Lyon VB; Holland KE
    Pediatr Dermatol; 2013; 30(6):e157-60. PubMed ID: 22612595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts.
    Komericki P; Akkilic-Materna M; Strimitzer T; Aberer W
    Sex Transm Dis; 2011 Mar; 38(3):216-8. PubMed ID: 20938374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impetigo as an adverse effect of topical 5% imiquimod treatment for viral warts.
    Heng LW; Chandran NS
    Int J Dermatol; 2021 Jul; 60(7):909-910. PubMed ID: 33660286
    [No Abstract]   [Full Text] [Related]  

  • 32. Imiquimod 5% cream: a topical immune response modifier.
    Marini M
    Int J Dermatol; 2002 May; 41 Suppl 1():1-2. PubMed ID: 12087812
    [No Abstract]   [Full Text] [Related]  

  • 33. [Imiquimod--clinical efficacy].
    Beutner KR
    Ann Dermatol Venereol; 2000; 127(10 Suppl):3S19-3S21. PubMed ID: 11116859
    [No Abstract]   [Full Text] [Related]  

  • 34. Imiquimod as an immune response modulator in infectious conditions.
    Skinner RB
    Postgrad Med; 2002 Dec; 112(6 Suppl Using):8-16. PubMed ID: 19667608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events?
    Serra MC; Menicanti C; Pennacchioli E; Tosti G
    An Bras Dermatol; 2014; 89(5):806-7. PubMed ID: 25184923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Imiquimod: immunologic-response modifier].
    Berman B
    Ann Dermatol Venereol; 2000; 127(10 Suppl):3S15-3S18. PubMed ID: 11116858
    [No Abstract]   [Full Text] [Related]  

  • 37. Aphthous vulvar ulcers: a paradoxal adverse effect at distance of topical imiquimod?
    Maroñas-Jiménez L; Morales-Raya C; Burillo-Martínez S; Velasco-Tamariz V; Rodríguez-Peralto JL; Vanaclocha-Sebastián F
    Eur J Obstet Gynecol Reprod Biol; 2016 Mar; 198():156-157. PubMed ID: 26330283
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of efficacy of topical imiquimod in the treatment of patchy alopecia areata.
    Koc E; Tunca M; Akar A; Kurumlu Z
    Int J Dermatol; 2008 Oct; 47(10):1088-9. PubMed ID: 18986369
    [No Abstract]   [Full Text] [Related]  

  • 39. Imiquimod applied topically: A novel immune response modifier.
    Tyring S
    Skin Therapy Lett; 2001 Mar; 6(6):1-4. PubMed ID: 11298484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Condylomata acuminata in the neovagina after male-to-female reassignment treated with CO2 laser and imiquimod.
    Matsuki S; Kusatake K; Hein KZ; Anraku K; Morita E
    Int J STD AIDS; 2015 Jun; 26(7):509-11. PubMed ID: 24970474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.